PMA device
Orbera Intragastric Balloon
Boston Scientific Corporation · Implant, Intragastric For Morbid Obesity (LTI, Class III) · First FDA decision Aug 5, 2015, newest Jan 5, 2026Obesity
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
10
PMA pathway
Device trials
8
Naming "Orbera"
MAUDE reports
1,093
Brand "Orbera", since 2015
PubMed studies
60
Mentioning "Orbera"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Orbera Intragastric Balloon
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 6 of 10 decisions filed under this name.
- ORBERA INTRAGASTRIC BALLOONPMA supplement
P140008-S028 · Decided Jan 5, 2026 · 46 days after receipt · Normal 180 Day Track No User Fee
Device type: IMPLANT, INTRAGASTRIC FOR MORBID OBESITY (LTI) · GI, Urology & Nephrology
- ORBERA Intragastric Balloon (IGB) System, Endoline PuncPMA supplement
P140008-S025 · Decided Dec 14, 2023 · 73 days after receipt · Normal 180 Day Track
Device type: IMPLANT, INTRAGASTRIC FOR MORBID OBESITY (LTI) · GI, Urology & Nephrology
- ORBERA Intragastric Balloon SystemPMA supplement
P140008-S019 · Decided Dec 2, 2020 · 177 days after receipt · Normal 180 Day Track No User Fee
Device type: IMPLANT, INTRAGASTRIC FOR MORBID OBESITY (LTI) · GI, Urology & Nephrology
3 more FDA decisions with a free account
Older decisions: P140008-S007, P140008-S003, P140008-S002, P140008
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Bariatric Surgery for the Treatment of Morbid Obesity - Facility Certification RequirementNational analysisReview closedCAG-00250R3Updated Sep 16, 2026
- Bariatric Surgery for the Treatment of Morbid ObesityNational analysisReview closedCAG-00250R2Updated Sep 16, 2026
- Bariatric Surgery for the Treatment of Morbid ObesityNational analysisReview closedCAG-00250RUpdated Sep 16, 2026
- Bariatric Surgery for Treatment of Co-Morbid Conditions Related to Morbid ObesityNational determinationOn the books100.1Updated Apr 9, 2025
- Bariatric Surgical Management of Morbid ObesityLocal determinationIn effectL35022Novitas Solutions, Inc.Updated May 7, 2021
- Surgical Management of Morbid ObesityLocal determinationIn effectL33411First Coast Service Options, Inc.Updated Oct 2, 2019
Clinical trials
Device studies on ClinicalTrials.gov that name "Orbera", any status and sponsor, newest update first.
- Orbera365 Intragastric Balloon System (Abbreviated as'Orbera365')Pivotal-lookingRecruiting
Boston Scientific CorporationPublic (BSX)
NCT07195708 · 144 participants (planned) · Start Jun 3, 2026 · Primary completion Jun 30, 2028
Device: Treatment group · For: Weight Loss
Sites: Shanghai, China
Apollo Endosurgery, Inc.Not on our public-company list
NCT04362774 · 25 participants · Start Feb 23, 2021 · Primary completion Feb 21, 2023
Device: ORBERA365 · For: Obesity; Overweight
Sites: Seville, Spain
Cleveland Clinic LondonAcademic, hospital or other
NCT06305208 · 300 participants (planned) · Start Feb 1, 2024 · Primary completion Feb 1, 2034
Device: Endoscopic gastric suturing; Endoscopic gastric plication and 4 more · For: Obesity; Diabetes Mellitus, Type 2
Sites: London, United Kingdom
5 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Orbera", and for the whole product code for context.
This brand
1,093 reports: 648 malfunction, 419 injury, 26 death
Whole product code LTI
5,233 reports: 2,779 malfunction, 2,372 injury, 70 death
Newest reports for this brand
3005099803-2026-04357 · Received Oct 28, 2026 · Event dated Aug 27, 2026
Device type: Implant, Intragastric For Morbid Obesity (LTI)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Unspecified Tissue Injury
3005099803-2026-04288 · Received Oct 26, 2026 · Event dated Dec 1, 2015
Device type: Implant, Intragastric For Morbid Obesity (LTI)
Device problem as coded: Inflation Problem; Migration
Patient problem as coded: Abdominal Pain; Gastritis; Nausea; Vomiting
3005099803-2026-04299 · Received Oct 26, 2026 · Event dated Jan 1, 2025
Device type: Implant, Intragastric For Morbid Obesity (LTI)
Device problem as coded: Use of Device Problem; Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Abdominal Pain; Nausea; Vomiting
2 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Orbera"[tiab]. The summary above synthesizes these.
- Drugs and devices for weight management.
Med Lett Drugs Ther · 2022
- Endoscopic Treatments for Obesity.
Pajot G, Calderon G, Acosta A · Curr Treat Options Gastroenterol · 2017Review
- Drugs and devices for weight management.
Med Lett Drugs Ther · 2025
- Building an endobariatric program: lessons learned.
Badurdeen D, Hedjoudje A, Itani M, et al. · Endosc Int Open · 2020Review
- Six intragastric balloons: Which to choose?
Stavrou G, Shrewsbury A, Kotzampassi K · World J Gastrointest Endosc · 2021Review
- Progress in the study of intragastric occupancy device for weight reduction.
Yu Q, Cao Y, Wang Z, et al. · Zhong Nan Da Xue Xue Bao Yi Xue Ban · 2023
- Gastric perforation during second intragastric balloon treatment: a case report.
Berger ME, Løve US · AME Case Rep · 2022Case Reports
- Improving Weight Loss by Combination of Two Temporary Antiobesity Treatments.
Genco A, Ienca R, Ernesti I, et al. · Obes Surg · 2018Randomized Controlled Trial
- Intragastric Balloon Treatment for Obesity: FDA Safety Updates.
Tate CM, Geliebter A · Adv Ther · 2018Letter, Research Support, N.I.H., Extramural
- Advances in endoscopic balloon therapy for weight loss and its limitations.
Vyas D, Deshpande K, Pandya Y · World J Gastroenterol · 2017Editorial
- Endoscopic intragastric balloon therapy for 15ߙyears in Japan: Results of nationwide surveys.
Ohta M, Maekawa S, Imazu H, et al. · Asian J Endosc Surg · 2021
Other devices of this type
Also filed under product code LTI.
- Lap-Band Adjustable Gastric Banding SystemMedtimo, Inc. · PMA 2023
- Obalon Balloon SystemMedtimo, Inc. · PMA 2022
- Bioenterics Lap-Band Adjustable Gastric Banding SystemMedtimo, Inc. · PMA 2003
- ReShape Integrated Dual Balloon SystemBoston Scientific Corporation · PMA 2018
- Allurion Gastric Balloon SystemAllurion Technologies, Inc. · PMA 2026
- Spatz3 Adjustable Balloon SystemSpatz Fgia, Inc. · PMA 2023
- Ethicon Endo-Surgery Curved Adjustable Gastric with Sutureless Port and ApplierObtech Medical GmbH · PMA 2016
- Realize Adjustable Gastric BandObtech Medical GmbH · PMA 2011
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.